Erasca, Inc.

NasdaqGS ERAS

Erasca, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2024: USD -155.21 M

Erasca, Inc. EBIT is USD -155.21 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -4.92% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Erasca, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -147.93 M, a -6.87% change year over year.
Erasca, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -138.42 M, a -76.42% change year over year.
Erasca, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -78.46 M.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

NasdaqGS: ERAS

Erasca, Inc.

CEO	Dr. Jonathan E. Lim M.D.
IPO Date	July 16, 2021
Location	United States
Headquarters	10835 Road to the Cure
Employees	126
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.

Key trends

Past 5 years